Centene Corporation (CNC)
NYSE · St. Louis, Missouri, USA · Founded 1984 · CEO Sarah London
Valuation summary
$233.97 fair value versus $65.58 in the market, a difference of +256.8%. Rated Strong Buy.
| Fair value per share | $233.97 |
| Current share price | $65.58 |
| Upside / downside | +256.8% |
| Bear case | $47.01 |
| Bull case | $537.57 |
| Discount rate (WACC) | 9.9% |
| Terminal growth | 2.40% |
| Market capitalisation | $32B |
| EV / Sales | 0.1x |
About Centene Corporation
Founded in 1984 by Elizabeth Brinn as a single Wisconsin health plan. Sarah London has been CEO since 2022. Centene is the largest US Medicaid managed care organisation, administering government health programmes for low-income populations across most states, plus a substantial marketplace insurance business. Revenue depends almost entirely on government contracts and reimbursement rates.
Investment case
- Scale leader in Medicaid managed care, an area states continue to outsource.
- Marketplace enrolment has grown substantially with enhanced subsidies.
- Trades at a low multiple relative to the broader managed care group.
Key risks
- Medicaid redeterminations left a sicker remaining membership, pressuring margins badly.
- State reimbursement rates have lagged actual medical cost trends.
- Expiry of enhanced marketplace subsidies is a direct and dated risk to enrolment.
Recent developments
- 2026-10-27 · Q3 health benefits ratio of 92.7% beats expectations and the 2026 adjusted EPS floor is lifted above $5.20; Medicare Advantage nears breakeven source
- 2026-10-01 · Wellcare unveiled its 2027 Medicare Advantage and prescription drug plan offerings. source
- 2026-08-17 · Centene said CFO Drew Asher will step down at end-2026, succeeded by Chris Neczypor on 1 January 2027, and reaffirmed 2026 adjusted EPS guidance above $4.80. source
Revenue by segment
| Medicaid | 55% |
| Marketplace | 25% |
| Medicare | 12% |
| Other | 8% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $231.6B | $4.3B |
| Year 2 | $266.6B | $5.3B |
| Year 3 | $301.8B | $6.3B |
| Year 4 | $335.8B | $7.5B |
| Year 5 | $367.3B | $8.6B |
What the street says
One of the most contested managed care names. Rate adequacy versus medical costs drives everything.
Comparable companies: HUM · DXCM · CAH · NTRA · MCK · MDLN · COR · RMD
Open the interactive model, price chart and sensitivity grid →